Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cytokinetics (CYTK)
NASDAQ:CYTK
Holding CYTK?
Track your performance easily
CYTK Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$30.68 - $110.25
Previous Close$49.86
Volume1.82M
Average Volume (3M)1.20M
Market Cap
$6.03B
Enterprise Value$5.26B
Total Cash (Recent Filing)$1.01B
Total Debt (Recent Filing)$238.15M
Price to Earnings (P/E)―
Beta0.93
Next Earnings
Feb 20, 2025EPS Estimate
-$1.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.39
Shares Outstanding118,014,240
10 Day Avg. Volume1,538,259
30 Day Avg. Volume1,203,779
Standard Deviation0.24
R-Squared0.03
Alpha0.04
Financial Highlights & Ratios
Price to Book (P/B)-415.50
Price to Sales (P/S)1873.05
Price to Cash Flow (P/CF)-14.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.63K
Enterprise Value/Gross Profit-16.29
Enterprise Value/Ebitda-10.85
Forecast
1Y Price Target
$82.38Price Target Upside72.81% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
Cytokinetics News
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentBayer plans to initiate a Phase 3 clinical trial of aficamten in Japan in patients with obstructive HCM, supporting potential marketing authorization.
Financial MilestonesCytokinetics is entitled to receive up to €490 million in commercial milestone payments and tiered royalties from future sales of aficamten in Japan.
Strategic PartnershipCytokinetics announced a deal with Bayer for exclusive development and commercialization of aficamten in Japan, unlocking more value from this best-in-class asset.
Bears Say
Acquisition ExpectationsShares may face some near-term pressure on the news as it suggests no imminent acquisition, which has been a key focus amongst investors.
Financial PerformanceCytokinetics had a quiet 3Q, in our view, marked by in-line revenues and a miss on GAAP EPS.
Safety ConcernsSafety was more problematic, where beyond high rates of GI issues, one patient’s LVEF dropped below 50%, raising the prospect of a potential REMS with negative commercial read-throughs.
---
Ownership Overview
0.72% Insiders
35.85% Mutual Funds
39.35% Other Institutional Investors
0.46% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CYTK FAQ
What was Cytokinetics’s price range in the past 12 months?
Cytokinetics lowest stock price was $30.68 and its highest was $110.25 in the past 12 months.
What is Cytokinetics’s market cap?
Currently, no data Available
When is Cytokinetics’s upcoming earnings report date?
Cytokinetics’s upcoming earnings report date is Feb 20, 2025 which is in 90 days.
How were Cytokinetics’s earnings last quarter?
Cytokinetics released its earnings results on Nov 06, 2024. The company reported -$1.36 earnings per share for the quarter, missing the consensus estimate of -$1.235 by -$0.125.
Is Cytokinetics overvalued?
According to Wall Street analysts Cytokinetics’s price is currently Undervalued.
Does Cytokinetics pay dividends?
Cytokinetics does not currently pay dividends.
What is Cytokinetics’s EPS estimate?
Cytokinetics’s EPS estimate is -$1.25.
How many shares outstanding does Cytokinetics have?
Cytokinetics has 118,014,240 shares outstanding.
What happened to Cytokinetics’s price movement after its last earnings report?
Cytokinetics reported an EPS of -$1.36 in its last earnings report, missing expectations of -$1.235. Following the earnings report the stock price went up 0.613%.
Which hedge fund is a major shareholder of Cytokinetics?
Among the largest hedge funds holding Cytokinetics’s share is Fisher Asset Management LLC. It holds Cytokinetics’s shares valued at 29M.
---
Cytokinetics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$82.38 (72.81% Upside)
$82.38 (72.81% Upside)
Blogger Sentiment
Bullish
CYTK Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 58.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $5.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 3.3%
Last 30 Days ▼ 3.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
54.31%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
93.90%
Trailing 12-Months
Company Description
Cytokinetics
Cytokinetics, Inc. operates as a biopharmaceutical company, which focuses on the discovery and development of muscle activators as potential treatment for debilitating diseases. It conducts a Phase 2 clinical trials program for tirasemtiv, including a Phase 2b clinical trial in patients with ALS, known as BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS). The company was founded on August 5, 1997 and is headquartered in South San Francisco, CA.
---
CYTK Earnings Call
Q3 2024
0:00 / 0:00
---
CYTK Stock 12 Month Forecast
Average Price Target
$82.38
▲(72.81% Upside)
Technical Analysis
Best Analysts Covering CYTK
1 Year
1 Year Success Rate
18/25 ratings generated profit
1 Year Average Return
+33.43%
reiterated a buy rating 11 months ago
Copying Charles Duncan's trades and holding each position for 1 Year would result in 72.00% of your transactions generating a profit, with an average return of +33.43% per trade.
---